Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis.

IF 1.3 Q4 PHARMACOLOGY & PHARMACY

Current Reviews in Clinical and Experimental Pharmacology Pub Date : 2023-01-01 DOI:10.2174/2772432817666220315144253

Avinash Kumar Singh, Anoop Kumar, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed, Manju Sharma

{"title":"Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis.","authors":"Avinash Kumar Singh, Anoop Kumar, Narendra Agrawal, Dinesh Bhurani, Rayaz Ahmed, Manju Sharma","doi":"10.2174/2772432817666220315144253","DOIUrl":null,"url":null,"abstract":"Background: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear.Aim: The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib.Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3.Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high.Conclusion: The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Reviews in Clinical and Experimental Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2772432817666220315144253","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear.

Aim: The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib.

Methods: The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3.

Results: A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high.

Conclusion: The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.

查看原文本刊更多论文

伊马替尼治疗的慢性髓系白血病患者贫血患病率:一项基于证据的荟萃分析

背景:伊马替尼是用于治疗慢性髓性白血病(CML)患者的酪氨酸激酶抑制剂之一。伊马替尼与CML患者贫血的确切关系尚不清楚。目的:本研究旨在了解伊马替尼治疗的慢性髓系白血病患者贫血的发生率。方法:截至2021年7月31日，在PubMed、Google scholar和临床试验注册数据库中检索相关文章。文章的质量采用纽卡斯尔-渥太华量表进行评估。使用StatsDirect统计分析软件V.3计算95% CI的患病率。结果:共发现18项研究包含3537例患者与分析相关。发现CML中贫血的总患病率为34% (95% CI: 23%-46%)。然而，研究之间的异质性很高。结论:监测血红蛋白水平和确定贫血原因是伊马替尼治疗CML患者的主要关注点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Reviews in Clinical and Experimental Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

4.80

自引率

9.10%

发文量